Please provide your email address to receive an email when new articles are posted on . Patients who received pharmacy consultation were more likely to be prescribed an SGLT2 inhibitor. More patients ...

Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 ...

SGLT2 inhibitors offer significant benefits in CKD and HF, yet remain underutilized in primary care settings. An interprofessional initiative developed a prescription algorithm to enhance SGLT2 ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

In a new study published in Kidney International, researchers report that drugs known as SGLT2 inhibitors prevented ...